ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
Food Funct 11(6):56645673 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
Darvin P, Toor SM, Sasidharan Nair V, Elkord E
During GLP-1 therapy, maintain regular thyroid function testing: baseline, 6 weeks, 12 weeks, and then every 3 months for the first year
2025) Unusual, acquired, or rapidly changing pigmentation where malignancy cannot be excluded - Evaluate promptly
Most people describe it as a light exfoliating sensation with no downtime, leaving skin feeling smoother and looking more radiant immediately afterwards.